Russia through the prism of the world biopharmaceutical market

Biotechnology
Journal
Dmitrij I. Bairamashvili graduated in
1980 from the Moscow Institute of Fine
Chemical Technology with an MSc. in
Chemical Engineering/Technology. He
obtained a PhD in chemistry in 1988
from VNII of antibiotics, DSc. (D. habil.)
in biotechnology from the Moscow
University of Fine Chemical Technology
in 2007. He is the author or co-author
of more than 80 scientific articles and
patents in the Russian Federation. After graduating and until 1990, he
worked in research, first at the Shemyakin Institute of Bioorganic
Chemistry on the structure and function of photoreceptor proteins and
peptides of natural origin (until 1984), and then for 6 years as a research
fellow at the All-Union Research Institute of Antibiotics on cyclopeptide
antibiotics of polymyxin group. Since 1990, he has worked
as a manager in different business structures. Since 1996, he is affiliated
at the Institute of Bioorganic Chemistry, first as senior research fellow
and deputy-chief of the pilot facility and currently as its chief. This
pilot facility, which employs 80 researchers and engineers, is involved
in the development and scaling up of various biotechnological and
biomedical projects – starting with human recombinant insulin production.
For this work Dr Bairamashvili was awarded in 2005 the Prize
of the Russian Government. Dr. Bairamashvili participates in the
preparation of sections of Pharmacopoeia of Russian Federation dealing
with recombinant pharmaceutical proteins.
[14] Devine, J. W, Cline, R. R, Farley, J. F., Follow-on biologics: competition
in the biopharmaceutical marketplace. J. Am. Pharm. Assoc.
2006, 46, 193–204.
[15] Wick, J. Y., Zanni, G. R., Biogenerics: potential benefits and obstacles.
Consult Pharm. 2006, 21, 208–221.
[16] Bartoshevich, I. E., Nys, P. S., Shviadas, V. I., Navashin, S. M., Status
and prospects in the use of biocatalysis in the synthesis of β-lactam
antibiotics (in Russian). Antibiot. Med. Biotekhnol. 1986, 31, 98–104.
[17] Chazov, E. I., Smirnov, V. N., Suvorova, L. A., Suvorov, A. V. et al., Effect
of the new Soviet thrombolytic preparation streptodecase on the
fibrinolysis system (in Russian). Kardiologiia 1981, 21, 18–21.
[18] Ovchinnikov, Y. A., Efimov, V. A., Chakhmakhcheva, O. G., Synthesis
of a polynucleotide corresponding to the promotor region of bacteriofage
fd DNA. FEBS Lett. 1979, 100, 341–346.
[19] Ovchinnikov, Y. A., Efimov, V. A., Ivanova, I. N., Synthesis of DNA
coding for human proinsulin. Gene 1984, 31, 65–78.
[20] Debabov, V. G., Tsygankov, Ju. D., Chistoserdov, A. Ju., Sverdlov, E.
D., et al. Method for producing human leukocyte interferon α-2 Pat.
SU1364343, 1988
[21] Pokrovskii, V. I., Zmyzgova, A. V., Murzabaeva, R. T., Fomina, T. N.
et al., Reactogenicity, toxicity and tolerance of reaferon in healthy
volunteers (in Russian). Zh. Mikrobiol. Epidemiol. Immunobiol. 1988,
1, 69–73.
[22] Gabrilovich, D. I., Serebrovskaia, L. V., Murzabaeva, R. T., Semashko,
M. I. et al., Effect of reaferon on the functional activity of peripheral
blood lymphocytes and neutrophils of volunteers (in Russian). Zh.
Mikrobiol. Epidemiol. Immunobiol. 1988, 3, 61–65.
[23] Malinovskaia, V. V., Murzabaeva, R. T., Manakhova, L. S., Mironova,
L. L., The functioning of the interferon system with different methods
and dosages of recombinant α 2-interferon (reaferon) administration
(in Russian). Vopr. Virusol. 1989, 34, 180–183.
16 © 2007 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
BTJ 07/07 | TD | DOI 10.1002/biot.200700091
Biotechnol. J. 2007, 2
Mikhail L. Rabinovich graduated from
the School of Chemistry, Lomonosov
State University of Moscow, in 1973
with an MSc. in Chemistry. He obtained
his PhD in Chemistry, Kinetics
and Catalysis in 1977. In 1987 he became
DSc. (= Dr. habil.) in Biochemistry
from A. N. Bach Institute of Biochemistry,
Russian Academy of Sciences.
Since 2000, he is Professor in
Biotechnology from the State Attestation Committee of Russian Federation.
From 1983 until the present time he has been affiliated at the
A. N. Bach Institute of Biochemistry, Russian Academy of Sciences,
and since 1998 as the Head of the Department of Environmental Biochemistry
(http://www.inbi.ras.ru/english/labs/rabinovich-eng.html).
For this research he was awarded the medal of the USSR State Exhibition
of Achievements in Science and Technology in 1984 and the
National Prize for Young Scientists in 1986. In 1988/1989, he was a
visiting scientist at Leipzig Institute of Biotechnology, Academy of
Sciences of GDR. From 1992 to 2003 he was a lecturing professor in
environmental biotechnology at the Department of Ecology, Russian
University of Peoples Friendship, Moscow. In 2004/2005, he was a
guest professor at the Chair of Microbiology of Bayreuth University
(Chairman: Prof. Ortwin Meyer), Germany. Dr. Rabinovich has supervised
13 PhD and DSc. students from different countries. His field of
expertise includes chemical enzymology, plant biopolymers, biofuels,
fungal degradation of xenobiotics. He is the author and co-author of
4 books, and ca. 100 reviews and research articles in refereed journals;
in addition, he holds■check■ 14 Russian patents, is a member of the
Advisory Board of the Biotechnology Journal (Wiley-VCH), and has
written ■check■Recent Patents in Biotechnology (Bentham), and
Research and Reviews in Biosciences (TSI).
[24] Pisarev, V. V., Does Russia have a chance of implementation of modern
biotech achievements in the medical industry? (in Russian).
Novosti med. biotekhnol. ■year, vol? page no?■www.bionews.ru/
news/Bio.htm
[25] Grigoriev, A. I., Malashenkov, D. K., The role of innovation in the development
of life sciences (in Russian). Medbioteck-3, December,
2006, Moscow (http://www.bioinnovation.ru/index?id=materials).
[26] Tel’nova, E., “Toll-free” prescription has become more expensive (in
Russian). Rossijskaya Gazeta 21.10.2006. 237, 19 (http://www.rg.ru).
[27] Fast growth of pharmaceutical market (in Russian). Moskovskie
apteki, 25.12.2006 (http://www.mosapteki.ru/modules/news/article.php?storyid=202).
[28] Stepanov, V. Doctor “Brand” (in Russian). SmartMoney 04.09.2006,
25 (25) (www.smoney.ru/article.shtml?2006/09/04/1255).
[29] DLO: Market and patient (in Russian). Moskovskie apteki. 2006, 7–8
(152), 7–11 (http://www.mosapteki.ru).
[30] Konov, A. L., Biopharmaceuticals: state-of-the-art and perspectives
(in Russian). Farmacevt. sluzhba 2006, 1, 22–29.
[31] Kulish, D. M., Can a “biogeneric revolution” happen in Russia? (in
Russian) Farmacevt. vestnik 2005, 16 (375), 26 (http://www.pharmvestnik.ru/cgi-bin/statya.pl?sid=9570).
[32] Schmidt, M., Babu, K. R., Khanna , N., Marten, S. et al., Temperatureinduced
production of recombinant human insulin in high-cell density
cultures of recombinant Escherichia coli. J. Biotechnol. 1999, 68,
71–83.
GALLEY PROOF